Zobrazeno 1 - 10
of 14
pro vyhledávání: '"M Izquierdo Navarro"'
Autor:
S Izquierdo Muñoz, MT Sánchez Sánchez, M Izquierdo Navarro, S Fernández Peña, ME Cárdaba García
Publikováno v:
Eur J Hosp Pharm
Background The implementing Law 1015/2009 normalises the compassionate use of investigational drugs, access to off-label and unauthorised drugs in Spain. Rituximab is an anti-CD20 monoclonal antibody widely used in off-label conditions to treat autoi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4832581c240fcffc96280a6d9ab5fc74
https://europepmc.org/articles/PMC7535219/
https://europepmc.org/articles/PMC7535219/
Autor:
M Izquierdo Navarro, S Fernández Peña, A Salvador Palacios, S Izquierdo Muñoz, ME Cárdaba García
Publikováno v:
European Journal of Hospital Pharmacy. 23:A15.1-A15
Background Mercaptopurine is indicated for the treatment of acute lymphoblastic leukaemia (ALL). In our country, there is no commercial presentation that allows proper dosage in paediatric patients. However, in March 2012, an expensive 20 mg/mL merca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d907075a98600af55260c390776ebd6b
https://doi.org/10.1136/ejhpharm-2016-000875.34
https://doi.org/10.1136/ejhpharm-2016-000875.34
Publikováno v:
European Journal of Hospital Pharmacy. 23:A198.3-A199
Background Commercial presentations of oral thioguanine suitable for dosing in paediatric patients diagnosed with acute lymphoblastic leukaemia (ALL) are not available in our country. Therefore, paediatricians in our hospital requested the pharmacy d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da849fa792802850ffa4c05da77e69cf
https://doi.org/10.1136/ejhpharm-2016-000875.449
https://doi.org/10.1136/ejhpharm-2016-000875.449
Autor:
V Cabezas Martín, C Cardaba Perez, L García López, C Matallana Martin, S Fernández Cañabate, M Izquierdo Navarro, MT Sánchez Sánchez, S Fernández Peña
Publikováno v:
European Journal of Hospital Pharmacy. 21:A109.1-A109
Background Eosinophilic esophagitis (EoE) is a clinicopathological disease characterised by oesophageal eosinophilia and gastrointestinal symptoms. It is caused by immunologic reactions to ingested and inhaled allergens. The diagnosis is considered i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad7538ac35aeee97e4fb9dc33edd011b
https://doi.org/10.1136/ejhpharm-2013-000436.268
https://doi.org/10.1136/ejhpharm-2013-000436.268
Autor:
M Izquierdo Navarro, L García López, C Cardaba Perez, C Matallana Martin, T Sánchez Sánchez, S Fernández Cañabate, V Cabezas Martín, S Fernández Peña
Publikováno v:
European Journal of Hospital Pharmacy. 21:A85.2-A86
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77170fcfbaaeb251675963aff0b0e047
https://doi.org/10.1136/ejhpharm-2013-000436.209
https://doi.org/10.1136/ejhpharm-2013-000436.209
Autor:
MT Sánchez Sánchez, M Izquierdo Navarro, C Cardaba Perez, C Matallana Martin, L García López, V Cabezas Martín, S Fernández Cañabate, S Fernández Peña
Publikováno v:
European Journal of Hospital Pharmacy. 21:A108.3-A109
Background Behcet’s disease (BD) is an inflammatory disease characterised by recurrent oral aphthous ulcers and numerous potential systemic manifestations. These include genital ulcers, ocular disease, skin lesions, neurological disease, vascular d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7f436e46b8d5f36f712592d7e1707d2
https://doi.org/10.1136/ejhpharm-2013-000436.267
https://doi.org/10.1136/ejhpharm-2013-000436.267
Autor:
S Fernández Peña, S Fernández Cañabate, MT Sánchez Sánchez, L García López, C Cardaba Perez, C Matallana Martin, M Izquierdo Navarro, V Cabezas Martín
Publikováno v:
European Journal of Hospital Pharmacy. 21:A75.3-A76
Background Given the high budgetary impact of antiretroviral therapy (ART) and the lack of adherence to sometimes complex HIV treatment, it is interesting to analyse the reasons for changes between different ARTs. Purpose To analyse the causes of cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df6c19227563a203b717342dce61246c
https://doi.org/10.1136/ejhpharm-2013-000436.186
https://doi.org/10.1136/ejhpharm-2013-000436.186
Autor:
A.M. López González, T Sánchez Sánchez, S Fernández Cañabate, A Salvador Palacios, C Matallana Martin, L García López, M Izquierdo Navarro, V Cabezas Martín, V Martínez Santana
Publikováno v:
European Journal of Hospital Pharmacy. 20:A106.1-A106
Background Infantile haemangiomas are common vascular tumours in children. Only 10–15% should be treated due to any vital, functional or aesthetic complication. Oral corticosteroids have been the primary treatment of choice. However, excellent outc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3171c88ed36eb33189f4885230b0ac7
https://doi.org/10.1136/ejhpharm-2013-000276.295
https://doi.org/10.1136/ejhpharm-2013-000276.295
Publikováno v:
European Journal of Hospital Pharmacy. 20:A113.3-A114
Background The implementing Law 1015/2009 normalises the compassionate use of investigational drugs, access to off-label and unauthorised drugs in Spain. Mycophenolate mofetil/Mycophenolic Acid (MM/MA) have been used in off-label conditions to treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4356a84ff358a46459bff245ffbb4fc7
https://doi.org/10.1136/ejhpharm-2013-000276.316
https://doi.org/10.1136/ejhpharm-2013-000276.316
Autor:
C Matallana Martin, M Izquierdo Navarro, A.M. López González, V Martínez Santana, MA Calleja Hernández, MT Sánchez Sánchez
Publikováno v:
European Journal of Hospital Pharmacy. 20:A149.1-A149
Background Several studies have evaluated quality of life (QoL) by filling in the EuroQoL-5D..In most of them, it is found that the two dimensions of EuroQoL-5D most associated with a poor QoL are pain/discomfort and anxiety/depression. Purpose To fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::173c69f82c9e4195a41ecfcc480c5c06
https://doi.org/10.1136/ejhpharm-2013-000276.412
https://doi.org/10.1136/ejhpharm-2013-000276.412